BioSpace News Archive

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual H.C. Wainwright Global Life Sciences Conference,

The Board of EpiEndo Pharmaceuticals is pleased to announce the appointment of Maria Bech, MSc as Chief Executive Officer (CEO) of the Company, effective immediately.

Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informed that it has uploaded to its investors website a corporate video about the progress on the New Industrial Cluster and the start of operations in the Personal Care Plant, and in the new Logistics Central Warehouse.

Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune diseases, is pleased to announce that one of its drugs produced strong effects in modulating gut microbiota in a mouse model study of inflammatory bowel disease.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming virtual investor conferences

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that its latest multiple sclerosis (MS) research will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from February 25-27 .

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber .

Mark Mallon named CEO effective April 2021; Douglas M. VanOort will retire as CEO and transition to executive chairman of the board of directors

-- Record Fourth-Quarter 2020 Net Sales of $745.3 Million Increased 105 Percent; Fourth-Quarter 2020 GAAP Net Income of $190.6 Million; Adjusted EBITDA of $371.0 Million --